Cantor Fitzgerald Reiterates Overweight Rating on Compass Therapeutics (CMPX) Ahead of PFS/OS Readout Mar 12, 2026 09:32AM
Cantor Fitzgerald Starts Compass Therapeutics (CMPX) at Overweight Dec 3, 2025 06:07AM
Compass Therapeutics to Participate in Upcoming Investor Events Aug 30, 2023 08:00AM
Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium Mar 28, 2023 08:30AM